## Special Issue

## Novel Biomarkers for Acute and Chronic Heart Failure

## Message from the Guest Editors

Heart failure is acknowledged as a major and growing public health problem. It is currently a devastating syndrome with a very negative impact on mortality, morbidity, and health-related quality of life. Heart failure is also considered an international priority in healthcare due to its growing prevalence and to the rising medical resource use and expenditure. The use of biomarkers in the management of patients with heart failure has increased over the past few years. Biomarkers contribute to making reliable tools for a systematic and optimized strategy in heart failure diagnosis and treatment. Recent advances in research have settled the basis for biomarker testing and diagnostic evaluation in heart failure; however, there are still many gaps of knowledge regarding the use of biomarkers for patient-centered integrated early diagnosis and risk stratification. This Special Issue will provide novel findings and innovations in the field of biomarkers, to ensure more efficiency for heart failure condition through multidisciplinary and integrated management approach.

#### **Guest Editors**

Dr. Josep Comín-Colet

- 1. Cardiology Department, Heart Institute, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
- 2. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
- 3. Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
- 4. Centro de Investigación Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain
- 5. Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain

Dr. Cristina Enjuanes-Grau

Hospital Universitari de Bellvitge, Barcelona, Spain

## Deadline for manuscript submissions

closed (10 July 2023)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/99164

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

